Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment

Mark S. Soloway, Joseph V. Briggman, Gennaro A. Carpinito, Gerald W. Chodak, Paul A. Church, Donald L. Lamm, Paul Lange, Edward Messing, Robert M. Pasciak, George B. Reservitz, Daniel B. Rukstalis, Michael F. Sarosdy, Walter M. Stadler, Robert P. Thiel, Cheryl L. Hayden

Research output: Contribution to journalArticle

271 Citations (Scopus)

Abstract

Purpose: We evaluated the ability of an immunoassay for nuclear matrix protein 22 (NMP22* test kit) to predict the subsequent disease status of patients with transitional cell carcinoma of the urinary tract at approximately 10 days after transurethral resection of bladder tumor. Materials and Methods: A total of 90 patients with transitional cell carcinoma provided voided urine samples at least 5 days postoperatively. NMP22 was determined using a commercial test kit. At initial cystoscopic examination 3 to 6 months later the disease status was recorded, and the NMP22 values before and after transurethral resection of bladder tumor were compared. Results: Of 125 followup cystoscopic examinations (60 patients had 1, 26 had 2, 3 had 3 and 1 had 4 recurrences) transitional cell carcinoma was pathologically confirmed in 33. No malignancy was present at 79 examinations (if tumor was seen endoscopically, pathological evaluation indicated atypia, dysplasia or no abnormality). NMP22 values in these 2 populations were significantly different (malignancy median 20.81 units per ml. and no malignancy median 5.72 units per ml., Mann-Whitney U test for differences between 2 medians p = 0.00005). Of the 33 recurrences 23 (70%) had NMP22 values greater than the reference range (10 units per ml.). Additionally, NMP22 identified all 6 subjects (100%) who had invasive disease 3 to 6 months later. Of 72 patients with NMP22 less than 10 units per ml. 62 (86%) had no malignancy at subsequent cystoscopy. Conclusions: NMP22 was highly predictive of tumor status at followup cystoscopy. This quantitative, noninvasive assay, with high negative predictive value (86%) and sensitivity to detect malignancy (100% for invasive disease and 70% overall), may be a helpful adjunct to cytology and endoscopy for monitoring disease status after endoscopic tumor resection.

Original languageEnglish
Pages (from-to)363-367
Number of pages5
JournalJournal of Urology
Volume156
Issue number2
StatePublished - Aug 1 1996

Fingerprint

Transitional Cell Carcinoma
Tumor Biomarkers
Urinary Tract
Neoplasms
Cystoscopy
Therapeutics
Urinary Bladder Neoplasms
nuclear matrix protein 22
Recurrence
Nonparametric Statistics
Immunoassay
Endoscopy
Cell Biology
Reference Values
Urine

Keywords

  • Biological
  • Immunoassay; carcinoma
  • Transitional cell; bladder neoplasms; tumor markers

ASJC Scopus subject areas

  • Urology

Cite this

Soloway, M. S., Briggman, J. V., Carpinito, G. A., Chodak, G. W., Church, P. A., Lamm, D. L., ... Hayden, C. L. (1996). Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. Journal of Urology, 156(2), 363-367.

Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. / Soloway, Mark S.; Briggman, Joseph V.; Carpinito, Gennaro A.; Chodak, Gerald W.; Church, Paul A.; Lamm, Donald L.; Lange, Paul; Messing, Edward; Pasciak, Robert M.; Reservitz, George B.; Rukstalis, Daniel B.; Sarosdy, Michael F.; Stadler, Walter M.; Thiel, Robert P.; Hayden, Cheryl L.

In: Journal of Urology, Vol. 156, No. 2, 01.08.1996, p. 363-367.

Research output: Contribution to journalArticle

Soloway, MS, Briggman, JV, Carpinito, GA, Chodak, GW, Church, PA, Lamm, DL, Lange, P, Messing, E, Pasciak, RM, Reservitz, GB, Rukstalis, DB, Sarosdy, MF, Stadler, WM, Thiel, RP & Hayden, CL 1996, 'Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment', Journal of Urology, vol. 156, no. 2, pp. 363-367.
Soloway, Mark S. ; Briggman, Joseph V. ; Carpinito, Gennaro A. ; Chodak, Gerald W. ; Church, Paul A. ; Lamm, Donald L. ; Lange, Paul ; Messing, Edward ; Pasciak, Robert M. ; Reservitz, George B. ; Rukstalis, Daniel B. ; Sarosdy, Michael F. ; Stadler, Walter M. ; Thiel, Robert P. ; Hayden, Cheryl L. / Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. In: Journal of Urology. 1996 ; Vol. 156, No. 2. pp. 363-367.
@article{f7067930e5d842868632cc22fc6d52f8,
title = "Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment",
abstract = "Purpose: We evaluated the ability of an immunoassay for nuclear matrix protein 22 (NMP22* test kit) to predict the subsequent disease status of patients with transitional cell carcinoma of the urinary tract at approximately 10 days after transurethral resection of bladder tumor. Materials and Methods: A total of 90 patients with transitional cell carcinoma provided voided urine samples at least 5 days postoperatively. NMP22 was determined using a commercial test kit. At initial cystoscopic examination 3 to 6 months later the disease status was recorded, and the NMP22 values before and after transurethral resection of bladder tumor were compared. Results: Of 125 followup cystoscopic examinations (60 patients had 1, 26 had 2, 3 had 3 and 1 had 4 recurrences) transitional cell carcinoma was pathologically confirmed in 33. No malignancy was present at 79 examinations (if tumor was seen endoscopically, pathological evaluation indicated atypia, dysplasia or no abnormality). NMP22 values in these 2 populations were significantly different (malignancy median 20.81 units per ml. and no malignancy median 5.72 units per ml., Mann-Whitney U test for differences between 2 medians p = 0.00005). Of the 33 recurrences 23 (70{\%}) had NMP22 values greater than the reference range (10 units per ml.). Additionally, NMP22 identified all 6 subjects (100{\%}) who had invasive disease 3 to 6 months later. Of 72 patients with NMP22 less than 10 units per ml. 62 (86{\%}) had no malignancy at subsequent cystoscopy. Conclusions: NMP22 was highly predictive of tumor status at followup cystoscopy. This quantitative, noninvasive assay, with high negative predictive value (86{\%}) and sensitivity to detect malignancy (100{\%} for invasive disease and 70{\%} overall), may be a helpful adjunct to cytology and endoscopy for monitoring disease status after endoscopic tumor resection.",
keywords = "Biological, Immunoassay; carcinoma, Transitional cell; bladder neoplasms; tumor markers",
author = "Soloway, {Mark S.} and Briggman, {Joseph V.} and Carpinito, {Gennaro A.} and Chodak, {Gerald W.} and Church, {Paul A.} and Lamm, {Donald L.} and Paul Lange and Edward Messing and Pasciak, {Robert M.} and Reservitz, {George B.} and Rukstalis, {Daniel B.} and Sarosdy, {Michael F.} and Stadler, {Walter M.} and Thiel, {Robert P.} and Hayden, {Cheryl L.}",
year = "1996",
month = "8",
day = "1",
language = "English",
volume = "156",
pages = "363--367",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment

AU - Soloway, Mark S.

AU - Briggman, Joseph V.

AU - Carpinito, Gennaro A.

AU - Chodak, Gerald W.

AU - Church, Paul A.

AU - Lamm, Donald L.

AU - Lange, Paul

AU - Messing, Edward

AU - Pasciak, Robert M.

AU - Reservitz, George B.

AU - Rukstalis, Daniel B.

AU - Sarosdy, Michael F.

AU - Stadler, Walter M.

AU - Thiel, Robert P.

AU - Hayden, Cheryl L.

PY - 1996/8/1

Y1 - 1996/8/1

N2 - Purpose: We evaluated the ability of an immunoassay for nuclear matrix protein 22 (NMP22* test kit) to predict the subsequent disease status of patients with transitional cell carcinoma of the urinary tract at approximately 10 days after transurethral resection of bladder tumor. Materials and Methods: A total of 90 patients with transitional cell carcinoma provided voided urine samples at least 5 days postoperatively. NMP22 was determined using a commercial test kit. At initial cystoscopic examination 3 to 6 months later the disease status was recorded, and the NMP22 values before and after transurethral resection of bladder tumor were compared. Results: Of 125 followup cystoscopic examinations (60 patients had 1, 26 had 2, 3 had 3 and 1 had 4 recurrences) transitional cell carcinoma was pathologically confirmed in 33. No malignancy was present at 79 examinations (if tumor was seen endoscopically, pathological evaluation indicated atypia, dysplasia or no abnormality). NMP22 values in these 2 populations were significantly different (malignancy median 20.81 units per ml. and no malignancy median 5.72 units per ml., Mann-Whitney U test for differences between 2 medians p = 0.00005). Of the 33 recurrences 23 (70%) had NMP22 values greater than the reference range (10 units per ml.). Additionally, NMP22 identified all 6 subjects (100%) who had invasive disease 3 to 6 months later. Of 72 patients with NMP22 less than 10 units per ml. 62 (86%) had no malignancy at subsequent cystoscopy. Conclusions: NMP22 was highly predictive of tumor status at followup cystoscopy. This quantitative, noninvasive assay, with high negative predictive value (86%) and sensitivity to detect malignancy (100% for invasive disease and 70% overall), may be a helpful adjunct to cytology and endoscopy for monitoring disease status after endoscopic tumor resection.

AB - Purpose: We evaluated the ability of an immunoassay for nuclear matrix protein 22 (NMP22* test kit) to predict the subsequent disease status of patients with transitional cell carcinoma of the urinary tract at approximately 10 days after transurethral resection of bladder tumor. Materials and Methods: A total of 90 patients with transitional cell carcinoma provided voided urine samples at least 5 days postoperatively. NMP22 was determined using a commercial test kit. At initial cystoscopic examination 3 to 6 months later the disease status was recorded, and the NMP22 values before and after transurethral resection of bladder tumor were compared. Results: Of 125 followup cystoscopic examinations (60 patients had 1, 26 had 2, 3 had 3 and 1 had 4 recurrences) transitional cell carcinoma was pathologically confirmed in 33. No malignancy was present at 79 examinations (if tumor was seen endoscopically, pathological evaluation indicated atypia, dysplasia or no abnormality). NMP22 values in these 2 populations were significantly different (malignancy median 20.81 units per ml. and no malignancy median 5.72 units per ml., Mann-Whitney U test for differences between 2 medians p = 0.00005). Of the 33 recurrences 23 (70%) had NMP22 values greater than the reference range (10 units per ml.). Additionally, NMP22 identified all 6 subjects (100%) who had invasive disease 3 to 6 months later. Of 72 patients with NMP22 less than 10 units per ml. 62 (86%) had no malignancy at subsequent cystoscopy. Conclusions: NMP22 was highly predictive of tumor status at followup cystoscopy. This quantitative, noninvasive assay, with high negative predictive value (86%) and sensitivity to detect malignancy (100% for invasive disease and 70% overall), may be a helpful adjunct to cytology and endoscopy for monitoring disease status after endoscopic tumor resection.

KW - Biological

KW - Immunoassay; carcinoma

KW - Transitional cell; bladder neoplasms; tumor markers

UR - http://www.scopus.com/inward/record.url?scp=0030213562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030213562&partnerID=8YFLogxK

M3 - Article

C2 - 8683680

AN - SCOPUS:0030213562

VL - 156

SP - 363

EP - 367

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -